New heart device aims to cut stroke risk without lifelong pills

NCT ID NCT07278869

First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 26 times

Summary

This early study tests a new device called the Append System in 15 adults with atrial fibrillation (a type of irregular heartbeat). The device is threaded through a blood vessel to close off a small pouch in the heart called the left atrial appendage, where clots often form. The goal is to see if the procedure is safe and can reduce stroke risk, potentially offering an alternative to long-term blood thinners.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-VALVULAR ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arrhythmia Research Group

    RECRUITING

    Jonesboro, Arkansas, 72401, United States

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Append System (a catheter-based device that closes the left atrial appendage by turning it inside out and tying it off)

What this could lead to

If this device works safely, it could offer a new way to lower stroke risk in people with atrial fibrillation who cannot take blood thinners long-term.

What could go wrong

This is a very early feasibility study with only 15 people, so results may not apply broadly. The procedure carries risks like stroke, bleeding, or heart sac inflammation.

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.